Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEX implant versus ranibizumab for diabetic macular edema
2011-005631-20Phase 3Completed
- Sponsor
- Allergan
- Start
- Feb 2012
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in diabetic macular edema (DME) comparing Ozurdex arm with Ranibizumab arm (2 arms). Primary endpoint: Average change from baseline in best-corrected visual acuity. Started Feb 2012; status: completed.
02
Drugs
ozurdexranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2011-005631-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005631-20.